FDA grants accelerated approval to Inovio Voceryq as first US plasmid DNA-based immunotherapy

The FDA has granted accelerated approval to Inovio's Voceryq, marking the first US authorisation of a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis.
Voceryq is designed to reduce the frequency of surgical papilloma removal in adults with HPV-associated recurrent respiratory papillomatosis and is administered using Inovio's CELLECTRA 5PSP electroporation device.
In the RRP-001 study, 7 of 26 efficacy-evaluable patients, approximately 27%, required no surgery during 12 months of follow-up, while continued marketing authorisation remains dependent on confirmatory evidence under the FDA's accelerated approval pathway.
Field | Content |
Article Type | Approvals |
Company | Inovio Pharmaceuticals |
Product | Voceryq |
Modality | Plasmid DNA-based immunotherapy |
Regulator | U.S. Food and Drug Administration |
Approval Type | Accelerated approval |
Approval Date | 30 October 2026 |
Regulatory Milestone | First plasmid DNA-based immunotherapy approved in the United States |
Indication | Recurrent respiratory papillomatosis in adults |
Disease Cause | Human papillomavirus infection |
Patient Population | Adults with recurrent respiratory papillomatosis |
Treatment Objective | Reduce the frequency of surgical papilloma excisions |
Administration Technology | CELLECTRA 5PSP electroporation device |
Clinical Study | RRP-001 |
Efficacy-Evaluable Population | 26 patients |
Surgery-Free Patients | 7 of 26 patients |
Reported Surgery-Free Proportion | Approximately 27% |
Reported Follow-Up | 12 months |
Regulatory Condition | Continued approval contingent on confirmatory evidence |
Geographic Scope | United States |
What Happened | The FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis. |
Why It Matters | The decision introduces the first FDA-approved plasmid DNA-based immunotherapy and a treatment approach intended to reduce repeated surgical interventions. |
Clinical Evidence | In RRP-001, seven of 26 efficacy-evaluable patients required no surgery during 12 months of follow-up. |
Key Takeaway | Voceryq establishes a new therapeutic modality in US regulatory practice, although confirmatory evidence remains necessary. |
What to Watch | Confirmatory clinical evidence, treatment adoption, durability of reduced surgical burden and post-approval safety monitoring. |
Primary Source | U.S. Food and Drug Administration |
Primary Source URL | https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis |
Relevant Date | 30 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comentários